Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Prognostic impact of co-occurring mutations in NPM1-mutated Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRafeh SafdarHDHardik DandYAYanal Alnimer

Discussion

Loading...

Member takes

Overview

Retrospective review shows co-mutations, especially dnmt3a, reduce remission rates in npm1-mutated aml.

Key Points

  • Assess the prognostic impact of co-occurring mutations in patients with NPM1-mutated acute myeloid leukemia (AML).
  • Retrospective review of adult AML patients diagnosed at the University of Kentucky Markey Cancer Center.
  • Co-mutation analysis performed using a 97-gene next-generation sequencing panel.
  • Treatment response assessed per ELN 2022 criteria, with survival analyses conducted using Kaplan–Meier.
  • Among 457 patients, 104 had NPM1 mutations; 79% achieved complete remission/CR with incomplete hematologic recovery.
  • Higher co-mutation burden was linked to lower odds of achieving remission and poorer RFS and OS.
  • Specific mutations in ASXL1 and TET2 were associated with significantly worse outcomes.

Cite This Study

Safdar et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0aahttps://doi.org/10.1182/blood-2025-1729
View Full Paper
Ask AI
Bookmark
Share